Trastuzumab and cardiac dysfunction: update on preclinical studies
PM Klein, N Dybdal - Seminars in oncology, 2003 - Elsevier
Trastuzumab, a humanized, recombinant antibody directed against HER2, can significantly
improve survival in women with HER2-positive metastatic breast cancer. Treatment with
trastuzumab has been associated with cardiac toxicity, most commonly manifested as
asymptomatic decreases in left ventricular ejection fraction on multiple gated acquisition
scans. These asymptomatic decreases appear to be reversible, and their clinical
significance is not well understood. Fortunately, studies are beginning to show that the …
improve survival in women with HER2-positive metastatic breast cancer. Treatment with
trastuzumab has been associated with cardiac toxicity, most commonly manifested as
asymptomatic decreases in left ventricular ejection fraction on multiple gated acquisition
scans. These asymptomatic decreases appear to be reversible, and their clinical
significance is not well understood. Fortunately, studies are beginning to show that the …
